Impact of intra-operative intraperitoneal chemotherapy on organ/space surgical site infection in patients with gastric cancer

Journal of Hospital Infection

Volumn 91, Issue 3, 2015, Pages 237-243

  Liu, X ^a   Duan, X ^a   Xu, J ^a   Jin, Q ^a   Chen, F ^a   Wang, P ^a   Yang, Y ^a   Tang, X ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Intra operative intraperitoneal chemotherapy; Organ space surgical site infection

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CHEMOSURGERY; COMORBIDITY; CONTROLLED STUDY; FEMALE; GASTRECTOMY; GASTROINTESTINAL SURGERY; GRAM NEGATIVE INFECTION; HOSPITALIZATION; HUMAN; INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PALLIATIVE THERAPY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; STOMACH CANCER; SURGICAL INFECTION; ADVERSE EFFECTS; AGED; DRUG THERAPY; MICROBIOLOGY; MIDDLE AGED; PARENTERAL DRUG ADMINISTRATION; PROCEDURES; STOMACH NEOPLASMS; SURGICAL WOUND INFECTION;

ADULT; AGED; DRUG THERAPY; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURGICAL WOUND INFECTION;

EID: 84945436020     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2015.05.017     Document Type: Article

References (31)

1. Correa P. Gastric cancer: overview. Gastroenterol Clin N Am 2013, 42:211-217.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Witkamp A.J., de Bree E., Van Goethem R., Zoetmulder F.A. Rationale and techniques of intra-operative hyperthemic intraperitoneal chemotherapy. Cancer Treat Rev 2001, 27:365-374.
4. Cabalag C.S., Chan S.T., Kaneko Y., Duong C.P. A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology. Gastric Cancer 2015, 18:11-22.
5. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014, 370:1198-1208.
6. Nosrati M., Boroumand M., Tahmasebi S., Sotoudeh M., Sheikhfathollahi M., Goodarzynejad H. Excess costs associated with common healthcare-associated infections in an Iranian cardiac surgical unit. J Hosp Infect 2010, 76:304-307.
7. Jenks P.J., Laurent M., McQuarry S., Watkins R. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect 2014, 86:24-33.
8. Limón E., Shaw E., Badia J.M., et al. Post-discharge surgical site infections after uncomplicated elective colorectal surgery: impact and risk factors. The experience of the VINCat Program. J Hosp Infect 2014, 86:127-132.
9. Staszewicz W., Eisenring M.C., Bettschart V., Harbarth S., Troillet N. Thirteen years of surgical site infection surveillance in Swiss hospitals. J Hosp Infect 2014, 88:40-47.
10. Angarita F.A., Acuna S.A., Torregrosa L., Tawil M., Escallon J., Ruíz Á. Perioperative variables associated with surgical site infection in breast cancer surgery. J Hosp Infect 2011, 79:328-332.
11. Leong G., Wilson J., Charlett A. Duration of operation as a risk factor for surgical site infection: comparison of English and US data. J Hosp Infect 2006, 63:255-262.
12. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999, 20:250-278. quiz 279-280.
13. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
14. Biondo S., Kreisler E., Fraccalvieri D., Basany E.E., Codina-Cazador A., Ortiz H. Risk factors for surgical site infection after elective resection for rectal cancer. A multivariate analysis on 2131 patients. Colorectal Dis 2012, 14:e95-e102.
15. Decker M.R., Greenblatt D.Y., Havlena J., Wilke L.G., Greenberg C.C., Neuman H.B. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery 2012, 152:382-388.
16. Turan A., Shao D., Salmasi V., et al. Chemotherapy within 30 days before surgery does not augment postoperative mortality and morbidity. Can J Anaesth 2012, 59:758-765.
17. Feng D., Leong M., Li T., Chen L., Li T. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World J Surg Oncol 2015, 13:11.
18. Utsumi M., Shimizu J., Miyamoto A., et al. Age as an independent risk factor for surgical site infections in a large gastrointestinal surgery cohort in Japan. J Hosp Infect 2010, 75:183-187.
19. Bot J., Piessen G., Robb W.B., Roger V., Mariette C. Advanced tumor stage is an independent risk factor of postoperative infectious complications after colorectal surgery: arguments from a case-matched series. Dis Colon Rectum 2013, 56:568-576.
20. Hennessey D.B., Burke J.P., Ni-Dhonochu T., Shields C., Winter D.C., Mealy K. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg 2010, 252:325-329.
21. Togo A., Coulibaly Y., Dembélé B.T., et al. Risk factors for surgical site infection in children at the teaching hospital Gabriel Touré, Bamako. J Hosp Infect 2011, 79:371-372.
22. Yanez J.A., Teng X.W., Roupe K.A., Fariss M.W., Davies N.M. Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase-2. J Pharm Pharm Sci 2003, 6:308-314.
23. Tsirigotis P., Triantafyllou K., Girkas K., et al. Keratinocyte growth factor is effective in the prevention of imestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008, 42:337-343.
24. Kohout P., Cerman J., Brátová M., Zadák Z. Small bowel permeability in patients with cytostatic therapy. Nutrition 1999, 15:546-549.
25. Abel E., Ekman T., Warnhammar E., Hultborn R., Jennische E., Lange S. Early disturbance of microvascular function precedes chemotherapy-induced intestinal injury. Dig Dis Sci 2005, 50:1729-1733.
26. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
27. Nagayoshi H., Fukatsu K., Ueno C., et al. 5-Fluorouracil infusion reduces gut-associated lymphoid tissue cell number and mucosal immunoglobulin A levels. J Parenter Enteral Nut 2005, 29:395-400.
28. van Vliet M.J., Harmsen H.J., de Bont E.S., Tissing W.J. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 2010, 6:e1000879.
29. Takechi H., Mawatari K., Harada N., et al. Glutamine protects the small intestinal mucosa in anticancer drug-induced rat enteritis model. J Med Invest 2014, 61:59-64.
30. Boukhettala N., Ibrahim A., Claeyssens S., et al. A diet containing whey protein, glutamine, and TGFβ modulates gut protein metabolism during chemotherapy-induced mucositis in rats. Dig Dis Sci 2010, 55:2172-2181.
31. Wang H., Geier M.S., Howarth G.S. Prebiotics: a potential treatment strategy for the chemotherapy-damaged gut?. Crit Rev Food Sci Nutr 2014 Aug 27, [Epub ahead of print].